Summary
In the ADVANZ-3 trial, among patients with advanced HIV-1, 96 weeks of daily combination treatment with efavirenz plus tenofovir/emtricitabine is as effective in increasing CD4+ T-cell levels as daily combination treatment using atazanavir/ritonavir plus tenofovir/emtricitabine or lopinavir/ritonavir plus tenofovir/emtricitabine. Similar improvements are also seen for inflammation, coagulation, and bacterial translocation markers.
- efavirenz
- HIV-1
- ADVANZ-3
- NCT00532168
- atazanavir/ritonavir
- lopinavir/ritonavir
- tenofovir/emtricitabine
- combined antiretroviral therapy
- HIV & AIDS
- infectious diseases clinical trials
- © 2015 SAGE Publications
Tools
Efavirenz-Based Therapy Effective in Highly Suppressed HIV-1–Infected Patients
Permalink:
Table of contents
Cited By...
- No citing articles found.